These encouraging in vitro and in vivo results from NIR-PIT against tumor biomarkers in preclinical models of lymphoma, bladder cancer, and EGFR+ or HER2+ solid tumors67 lay a foundation for continued studies of NIR-PIT targeting various tumor antigens including podoplanin (PDPN),68 delta-like protein 3 (DLL3),69 and prostate-specific membrane antigen (PSMA)70 (Table 1). This evidence concerns the gene DLL3 and neoplasm.